Compare SCZM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCZM | CDNA |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | SCZM | CDNA |
|---|---|---|
| Price | $9.99 | $17.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.33 |
| AVG Volume (30 Days) | 396.0K | ★ 617.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $22.30 | $15.37 |
| Revenue Next Year | $69.17 | $11.23 |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $8.92 | $10.96 |
| 52 Week High | $17.65 | $21.49 |
| Indicator | SCZM | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 38.95 |
| Support Level | $8.92 | $16.74 |
| Resistance Level | $12.81 | $18.02 |
| Average True Range (ATR) | 0.74 | 0.86 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 29.18 | 28.10 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.